DuPont™ Liveo™ BIO-PSAs enable development of new topical patch

Drossapharm AG relies on DuPont pressure sensitive adhesive expertise and products to develop LIXIM® Patch with etofenamate

Patches generally are regarded as advanced drug delivery systems whose structure and composition are fundamentally different from those of conventional semisolid dosage forms and whose design characteristics are specifically geared towards controlled, sustained drug delivery with minimized application frequency. Drossapharm has built a strong expertise in topical drug delivery and values the unique benefits of patch solutions.

Drossapharm selected DuPont for its expertise in the medical and pharmaceutical space, the Liveo™ product quality, and the technical support. DuPont’s experts provided deep insights into the structure and properties of the pressure sensitive adhesive (PSA) polymers, enabling Drossapharm to target the release of etofenamate from the patch to develop its LIXIM® Patch for a 24-hour application.